Copyright © 2010 IUPHAR
Annotated and expert reviewed. Please contact us if you can help with updates.
5-HT1A
Structural Information  |
|
class A G protein-coupled receptor |
| Species |
TM |
AA |
Chromosomal Location |
Gene Name |
Reference |
| Human |
7 |
422 |
5q11.2-q13 |
HTR1A
|
3-4 |
| Rat |
7 |
422 |
2q16 |
Htr1a
|
1-2 |
| Mouse |
7 |
421 |
13 D2.1 |
Htr1a
|
5 |
|
|
Database Links  |
|
ChEMBL Target |
51 (Hs), 11863 (Mm), 10576 (Rn) |
|
Ensembl |
ENSG00000178394 (Hs), ENSMUSG00000021721 (Mm), ENSRNOG00000010254 (Rn) |
|
Entrez Gene |
3350 (Hs), 15550 (Mm), 24473 (Rn) |
|
GeneCards |
HTR1A (Hs) |
|
HomoloGene |
20148 (Hs) |
|
OMIM |
109760 (Hs) |
|
PharmGKB Gene |
PA192 (Hs) |
|
Protein Ontology (PRO) |
PRO:000001161 (Hs) |
|
RefSeq Nucleotide |
NM_000524 (Hs), NM_008308 (Mm), NM_012585 (Rn) |
|
RefSeq Protein |
NP_000515 (Hs), NP_032334 (Mm), NP_036717 (Rn) |
|
UniGene Hs. |
247940 (Hs) |
|
UniProt |
P08908 (Hs), Q64264 (Mm), P19327 (Rn) |
|
Wikipedia |
5-HT1A |
| Search for 3D structures on the PDB |
|
Search using keywords: 5-Hydroxytryptamine receptors 5-HT1A
|
Search using accession numbers: P19327 || P08908 || Q64264
|
| Agonists |
|
Key to terms and symbols
|
View all chemical structures |
Click column headers to sort
|
| Ligand |
|
|
|
|
|
[3H]8-OH-DPAT
|
|
|
|
|
Hs |
Full agonist |
6.0 – 9.4 |
pKd |
48,50,52,62 |
|
[3H]S-15535
|
|
|
|
|
Hs |
Partial agonist |
5.8 – 5.9 |
pKd |
50 |
|
S-14671
|
|
|
|
|
Hs |
Full agonist |
10.2 – 10.5 |
pKi |
47,50 |
|
LY293284
|
|
|
|
|
Hs |
Full agonist |
10.1 |
pKi |
62 |
|
5-CT
|
|
|
|
|
Hs |
Full agonist |
9.4 – 10.3 |
pKi |
21,47,50-51 |
|
lisuride
|
|
|
|
|
Hs |
Full agonist |
9.7 – 9.8 |
pKi |
50-51,69 |
|
U92012A
|
|
|
|
|
Hs |
Full agonist |
9.7 |
pKi |
68 |
|
roxindole
|
|
|
|
|
Hs |
Partial agonist |
9.4 – 9.9 |
pKi |
48,69 |
|
S-14506
|
|
|
|
|
Hs |
Full agonist |
9.6 – 9.7 |
pKi |
47,50 |
|
5-HT
|
|
|
|
|
Hs |
Full agonist |
9.1 – 9.7 |
pKi |
21,47-48,50-52 |
|
(+)-flesinoxan
|
|
|
|
|
Hs |
Full agonist |
9.3 |
pKi |
47 |
|
L-694,247
|
|
|
|
|
Hs |
Full agonist |
9.3 |
pKi |
51 |
|
S-15535
|
|
|
|
|
Hs |
Partial agonist |
9.2 |
pKi |
50 |
|
LSD
|
|
|
|
|
Hs |
Full agonist |
9.0 |
pKi |
61 |
|
RU 24969
|
|
|
|
|
Hs |
Full agonist |
9.0 |
pKi |
47 |
|
8-OH-DPAT
|
|
|
|
|
Hs |
Full agonist |
8.4 – 9.4 |
pKi |
21,47,50,52-56 |
|
LY 165,163
|
|
|
|
|
Hs |
Full agonist |
8.9 |
pKi |
47 |
|
spiroxatrine
|
|
|
|
|
Hs |
Full agonist |
8.8 |
pKi |
47 |
|
ipsapirone
|
|
|
|
|
Hs |
Partial agonist |
8.6 – 8.8 |
pKi |
47,50 |
|
FG-5893
|
|
|
|
|
Hs |
Full agonist |
8.7 |
pKi |
47 |
|
pergolide
|
|
|
|
|
Hs |
Partial agonist |
8.7 |
pKi |
69 |
|
7-methoxy-1-naphthylpiperazine
|
|
|
|
|
Hs |
Full agonist |
8.6 |
pKi |
49 |
|
terguride
|
|
|
|
|
Hs |
Partial agonist |
8.5 |
pKi |
69 |
|
S 16924
|
|
|
|
|
Hs |
Partial agonist |
8.4 |
pKi |
66 |
|
ziprasidone
|
|
|
|
|
Hs |
Partial agonist |
7.9 – 8.9 |
pKi |
47,65 |
|
aripiprazole
|
|
|
|
|
Hs |
Full agonist |
8.2 |
pKi |
70 |
|
tandospirone
|
|
|
|
|
Hs |
Full agonist |
8.2 |
pKi |
47 |
|
ORG-5222
|
|
|
|
|
Hs |
Full agonist |
8.0 – 8.3 |
pKi |
47,65 |
|
zalospirone
|
|
|
|
|
Hs |
Full agonist |
8.1 |
pKi |
47 |
|
1-naphthylpiperazine
|
|
|
|
|
Hs |
Full agonist |
8.0 |
pKi |
49 |
|
ocaperidone
|
|
|
|
|
Hs |
Full agonist |
8.0 |
pKi |
22 |
|
bromocriptine
|
|
|
|
|
Hs |
Partial agonist |
7.9 |
pKi |
69 |
|
buspirone
|
|
|
|
|
Hs |
Partial agonist |
7.7 – 8.0 |
pKi |
21,47,50 |
|
LY334370
|
|
|
|
|
Hs |
Full agonist |
7.8 |
pKi |
63 |
|
BRL-15572
|
|
|
|
|
Hs |
Partial agonist |
7.7 |
pKi |
58 |
|
cabergoline
|
|
|
|
|
Hs |
Full agonist |
7.7 |
pKi |
69 |
|
donitriptan
|
|
|
|
|
Hs |
Full agonist |
7.6 |
pKi |
71 |
|
eletriptan
|
|
|
|
|
Hs |
Full agonist |
7.4 |
pKi |
72 |
|
naratriptan
|
|
|
|
|
Hs |
Full agonist |
7.1 – 7.6 |
pKi |
51,72 |
|
nafadotride
|
|
|
|
|
Hs |
Full agonist |
7.3 |
pKi |
47 |
|
BMY-14802
|
|
|
|
|
Hs |
Full agonist |
7.2 |
pKi |
47 |
|
xanomeline
|
|
|
|
|
Hs |
Full agonist |
7.2 |
pKi |
73 |
|
GR-127935
|
|
|
|
|
Hs |
Partial agonist |
7.1 – 7.2 |
pKi |
49,58 |
|
apomorphine
|
|
|
|
|
Hs |
Partial agonist |
6.9 |
pKi |
69 |
|
clozapine
|
|
|
|
|
Hs |
Full agonist |
6.8 – 6.9 |
pKi |
47,65-66 |
|
EMDT
|
|
|
|
|
Hs |
Full agonist |
6.8 |
pKi |
59 |
|
fluparoxan
|
|
|
|
|
Hs |
Partial agonist |
6.8 |
pKi |
54 |
|
zolmitriptan
|
|
|
|
|
Hs |
Full agonist |
6.6 |
pKi |
72 |
|
quetiapine
|
|
|
|
|
Hs |
Full agonist |
6.5 – 6.6 |
pKi |
47,65 |
|
piribedil
|
|
|
|
|
Hs |
Partial agonist |
6.4 |
pKi |
69 |
|
rizatriptan
|
|
|
|
|
Hs |
Full agonist |
6.4 |
pKi |
72 |
|
LY344864
|
|
|
|
|
Hs |
Full agonist |
6.3 |
pKi |
64 |
|
SB 216641
|
|
|
|
|
Hs |
Partial agonist |
6.3 |
pKi |
58 |
|
CP 93129
|
|
|
|
|
Hs |
Full agonist |
6.1 |
pKi |
51 |
|
SL65.0155
|
|
|
|
|
Hs |
Partial agonist |
6.0 |
pKi |
67 |
|
sumatriptan
|
|
|
|
|
Hs |
Full agonist |
6.0 |
pKi |
72 |
|
(-)-quinpirole
|
|
|
|
|
Hs |
Full agonist |
5.8 |
pKi |
48 |
|
olanzapine
|
|
|
|
|
Hs |
Full agonist |
5.6 – 5.8 |
pKi |
47,65 |
|
BMY-7378
|
|
|
|
|
Hs |
Partial agonist |
6.8 – 8.0 |
pIC50 |
57 |
|
L-772,405
|
|
|
|
|
Hs |
Full agonist |
7.2 |
pIC50 |
60 |
|
| Antagonists |
|
Key to terms and symbols
|
View all chemical structures |
Click column headers to sort
|
| Ligand |
|
|
|
|
|
[3H]NAD 299
|
|
|
|
|
Hs |
Antagonist |
9.8 |
pKd |
80 |
|
[3H]-p-MPPF
|
|
|
|
|
Hs |
Antagonist |
8.4 |
pKd |
52 |
|
Rec 15/3079
|
|
|
|
|
Hs |
Antagonist |
9.7 |
pKi |
77 |
|
NAN 190
|
|
|
|
|
Hs |
Antagonist |
9.4 |
pKi |
47 |
|
repinotan
|
|
|
|
|
Hs |
Antagonist |
9.4 |
pKi |
53 |
|
NAD 299
|
|
|
|
|
Hs |
Antagonist |
9.2 |
pKi |
76 |
|
SB 649915
|
|
|
|
|
Hs |
Antagonist |
8.6 |
pKi |
79 |
|
WAY-100635
|
|
|
|
|
Hs |
Antagonist |
7.9 – 9.2 |
pKi |
47,50 |
|
p-MPPI
|
|
|
|
|
Hs |
Antagonist |
8.4 |
pKi |
52 |
|
tiospirone
|
|
|
|
|
Hs |
Antagonist |
8.3 |
pKi |
47 |
|
(+)-UH 301
|
|
|
|
|
Hs |
Antagonist |
7.9 – 8.6 |
pKi |
47 |
|
(-)-tertatolol
|
|
|
|
|
Hs |
Antagonist |
8.2 |
pKi |
47,56 |
|
pindolol
|
|
|
|
|
Hs |
Antagonist |
8.1 |
pKi |
50 |
|
SB 272183
|
|
|
|
|
Hs |
Antagonist |
8.0 |
pKi |
78 |
|
WAY-100135
|
|
|
|
|
Hs |
Antagonist |
8.0 |
pKi |
50 |
|
methiothepin
|
|
|
|
|
Hs |
Antagonist |
7.8 – 8.1 |
pKi |
47,50 |
|
spiperone
|
|
|
|
|
Hs |
Antagonist |
6.7 – 8.8 |
pKi |
21,47,50 |
|
(-)-propranolol
|
|
|
|
|
Hs |
Antagonist |
7.5 |
pKi |
51 |
|
(S)-flurocarazolol
|
|
|
|
|
Hs |
Antagonist |
7.5 |
pKi |
74 |
|
pizotifen
|
|
|
|
|
Hs |
Antagonist |
7.4 |
pKi |
51 |
|
GR 125,743
|
|
|
|
|
Hs |
Antagonist |
7.3 |
pKi |
51 |
|
yohimbine
|
|
|
|
|
Hs |
Antagonist |
7.3 |
pKi |
54 |
|
fluspirilene
|
|
|
|
|
Hs |
Antagonist |
7.2 |
pKi |
65 |
|
thioridazine
|
|
|
|
|
Hs |
Antagonist |
7.1 |
pKi |
47 |
|
iloperidone
|
|
|
|
|
Hs |
Antagonist |
7.0 |
pKi |
82 |
|
GR 218,231
|
|
|
|
|
Hs |
Antagonist |
6.8 |
pKi |
75 |
|
iloperidone
|
|
|
|
|
Rn |
Antagonist |
6.8 |
pKi |
81 |
|
pimozide
|
|
|
|
|
Hs |
Antagonist |
6.8 |
pKi |
47 |
|
(R)-flurocarazolol
|
|
|
|
|
Hs |
Antagonist |
6.5 |
pKi |
74 |
|
SB 714786
|
|
|
|
|
Hs |
Antagonist |
6.5 |
pKi |
79 |
|
sertindole
|
|
|
|
|
Hs |
Antagonist |
6.4 – 6.6 |
pKi |
47,65 |
|
zotepine
|
|
|
|
|
Hs |
Antagonist |
6.5 |
pKi |
65 |
|
risperidone
|
|
|
|
|
Hs |
Antagonist |
6.4 – 6.5 |
pKi |
47,65 |
|
(+)-butaclamol
|
|
|
|
|
Hs |
Antagonist |
6.4 |
pKi |
47 |
|
cyamemazine
|
|
|
|
|
Hs |
Antagonist |
6.3 |
pKi |
55 |
|
9-OH-risperidone
|
|
|
|
|
Hs |
Antagonist |
6.2 |
pKi |
65 |
|
chlorpromazine
|
|
|
|
|
Hs |
Antagonist |
6.2 |
pKi |
47 |
|
risperidone
|
|
|
|
|
Rn |
Antagonist |
6.2 |
pKi |
81 |
|
MPDT
|
|
|
|
|
Hs |
Antagonist |
5.8 |
pKi |
59 |
|
haloperidol
|
|
|
|
|
Hs |
Antagonist |
5.7 – 5.8 |
pKi |
47,56,65-66 |
|
pipamperone
|
|
|
|
|
Hs |
Antagonist |
5.6 |
pKi |
65 |
|
raclopride
|
|
|
|
|
Hs |
Antagonist |
5.2 |
pKi |
47 |
|
ketanserin
|
|
|
|
|
Hs |
Antagonist |
5.0 |
pKi |
21 |
|
SDZ-216525
|
|
|
|
|
Hs |
Antagonist |
7.8 – 8.2 |
pIC50 |
57 |
|
ritanserin
|
|
|
|
|
Hs |
Antagonist |
5.2 – 5.5 |
pIC50 |
57 |
|
|
View species-specific antagonist tables
|
Primary Transduction Mechanisms
|
| Transducer |
Effector/Response |
|
Gi/Go family |
Adenylate cyclase inhibition |
Secondary Transduction Mechanisms  |
| Transducer |
Effector/Response |
|
|
Phospholipase C stimulation |
Tissue Distribution
|
| Limbic system: septum, hippocampus, thalamus, amygdala, olfactory bulb, medulla, mesencephalon, hypothalamus. |
| Species: |
Rat |
| Technique: |
Northern blotting. |
| References: |
2 |
|
|
| Kidney: medullary and cortical thick ascending limbs (TAL), distal convoluted tubules (DCT), connecting tubule cells, principal cells of the initial collecting tubule. |
| Species: |
Rat |
| Technique: |
Immunohistochemistry. |
| References: |
24 |
|
|
| Benign and malignant prostate tissue. |
| Species: |
Human |
| Technique: |
Western blotting. |
| References: |
25 |
|
|
| Posterior taste buds. |
| Species: |
Rat |
| Technique: |
RT-PCR. |
| References: |
26 |
|
|
| Peritoneal macrophages. |
| Species: |
Mouse |
| Technique: |
Immunohistochemistry. |
| References: |
27 |
|
|
| Brain: pyramidal and principal cells and calbindin- and parvalbumin-containing neurons. |
| Species: |
Rat |
| Technique: |
Immunohistochemistry. |
| References: |
28 |
|
|
| Poorly expressed in coronary arteries, atrium, ventricle and epicardium. |
| Species: |
Human |
| Technique: |
RT-PCR. |
| References: |
29 |
|
|
| Spinal cord: dorsal horn > ventral horn. |
| Species: |
Human |
| Technique: |
Radioligand binding. |
| References: |
30 |
|
|
| CNS: dentate gyrus, hippocampus (all fields especially CA1), subiculum, parahippocampal gyrus and neocortical regions (superficial and middle laminae), raphe of the brainstem. |
| Species: |
Human |
| Technique: |
in situ hybridisation. |
| References: |
31 |
|
|
| CNS: Dorsal raphe nucleus, septum, hippocampus, entorhinal cortex, interpeduncular nucleus > olfactory bulb, cerebral cortex, thalamic and hypothalamic nuclei, nuclei of the brainstem, dorsal horn of the spinal cord. |
| Species: |
Rat |
| Technique: |
in situ hybridisation. |
| References: |
32 |
|
|
| Superior cervical ganglia, lumbar sympathetic ganglia. |
| Species: |
Rat |
| Technique: |
RT-PCR. |
| References: |
33 |
|
|
| Kidney: medullary and cortical thick ascending limbs (TAL), distal convoluted tubules (DCT), connecting tubule cells, principal cells of the initial collecting tubule. |
| Species: |
Human |
| Technique: |
Immunohistochemistry. |
| References: |
24 |
|
|
Functional Assays
|
| Measurement of cAMP levels in COS-7 cells transfected with the 5-HT1A receptor. |
| Species: |
Human |
| Tissue: |
COS-7 |
| Response measured: |
Inhibition of cAMP accumulation. |
| References: |
3,21 |
|
|
| Measurement of IP3 levels in HeLa cells transfected with the 5-HT1A receptor. |
| Species: |
Human |
| Tissue: |
HeLa cells. |
| Response measured: |
PLC mediated IP3 accumulation. |
| References: |
3 |
|
|
| Measurement of cAMP levels in rat CH4ZD10 cells endogenously expressing the 5-HT1A receptor. |
| Species: |
Rat |
| Tissue: |
CH4ZD10 cells. |
| Response measured: |
PTX-sensitive inhibition of cAMP accumulation. |
| References: |
2 |
|
|
| Measurement of cAMP levels in SN-48 cells endogenously expressing the 5-HT1A receptor. |
| Species: |
Mouse |
| Tissue: |
Differentiated SN-48 cell line. |
| Response measured: |
Inhibition of cAMP accumulation. |
| References: |
5 |
|
|
| Measurement of cAMP levels in HEK 293 cells transfected with the rat 5-HT1A receptor alone/with adenylyl cyclase II (ACII). |
| Species: |
Rat |
| Tissue: |
HEK 293 cells. |
| Response measured: |
Inhibition of cAMP accumulation in the absence of ACII. Increase in cAMP accumulation in the presence of ACII. |
| References: |
6 |
|
|
| Measurement of extracellular acidification rate (ECAR) in CHO-K1 cells transfected with the 5-HT1A receptor. |
| Species: |
Human |
| Tissue: |
CHO-K1 cells. |
| Response measured: |
Activation of the Na+/H+ exchanger. |
| References: |
22 |
|
|
| Measurement of phosphorylated ERK1/2 levels in the rat hippocampus. |
| Species: |
Rat |
| Tissue: |
Hippocampus. |
| Response measured: |
Inhibition of the Erk1/2 MAPK pathway. |
| References: |
23 |
|
|
Physiological Functions
|
| Stimulation of cell proliferation. |
| Species: |
Human |
| Tissue: |
DU145, PC-3, LNCaP and hPCP prostatic cell lines. |
| References: |
25 |
|
|
| Increase in phagocytic activity. |
| Species: |
Mouse |
| Tissue: |
Peritoneal macrophages. |
| References: |
27 |
|
|
| Hyperpolarisation of orexin neurons. |
| Species: |
Mouse |
| Tissue: |
Hypothalamus. |
| References: |
34 |
|
|
| Regulation of sleep-wakefulness cycles. |
| Species: |
Rat |
| Tissue: |
In vivo. |
| References: |
35-36 |
|
|
| Regulation of sleep-wakefulness cycles. |
| Species: |
Mouse |
| Tissue: |
In vivo. |
| References: |
8 |
|
|
| Regulation of epileptic activity. |
| Species: |
Rat |
| Tissue: |
In vivo. |
| References: |
37 |
|
|
| Regulation of oxytocin and adrenocorticotropin hormone release. |
| Species: |
Rat |
| Tissue: |
In vivo (paraventricular nucleus). |
| References: |
38 |
|
|
| Adult brain cell proliferation. |
| Species: |
Rat |
| Tissue: |
Subgranular layer (SGL) of the dentate gyrus (DG) and the subventricular zone (SVZ). |
| References: |
39 |
|
|
| Autoreceptor: autoinhibitory control. |
| Species: |
Mouse |
| Tissue: |
In vivo (dorsal raphe nucleus). |
| References: |
9 |
|
|
| Regulation of cholinergic, GABAergic and glutamatergic transmission and hence cognitive performance. |
| Species: |
Mouse |
| Tissue: |
In vivo. |
| References: |
40 |
|
|
| Regulation of anxiety-like behaviour. |
| Species: |
Mouse |
| Tissue: |
In vivo. |
| References: |
10 |
|
|
| Regulation of stress responses and locomotor activity. |
| Species: |
Mouse |
| Tissue: |
In vivo (hypothalamus). |
| References: |
41 |
|
|
| Regulation of aggressive bahaviour. |
| Species: |
Rat |
| Tissue: |
In vivo. |
| References: |
42 |
|
|
| Regulation of feeding behaviour by inducing preproNPY mRNA expression. |
| Species: |
Rat |
| Tissue: |
In vivo (arcuate nucleus). |
| References: |
43 |
|
|
| Facilitation of autoshaped learning. |
| Species: |
Mouse |
| Tissue: |
In vivo. |
| References: |
17 |
|
|
| Regulation of hippocampal functions. |
| Species: |
Rat |
| Tissue: |
In vivo. |
| References: |
44 |
|
|
| Antinociception. |
| Species: |
Rat |
| Tissue: |
In vivo. |
| References: |
45-46 |
|
|
Physiological Consequences of Altering Gene Expression
|
| 5-HT1A receptor knockout mice exhibit higher amounts of paradoxical sleep than wild-type mice during both the light and the dark phases. |
| Species: |
Mouse |
| Tissue: |
|
| Technique: |
Gene targeting in embryonic stem cells. |
| References: |
8 |
|
|
| 5-HT1A receptor knockout mice have an increased responsiveness to 5-HT in the dorsal raphe nucleus due to lack of autoinhibitory control by 5-HT1A autoreceptors. |
| Species: |
Mouse |
| Tissue: |
|
| Technique: |
Gene targeting in embryonic stem cells. |
| References: |
9 |
|
|
| Increased 5-HT1A receptor expression during postnatal development caused elevated 5-HT levels in the hippocampus and striatum, decreased anxiety-like behaviour (in male and female) and decreased body temperature (male only). |
| Species: |
Mouse |
| Tissue: |
|
| Technique: |
Transgenesis. |
| References: |
10 |
|
|
| Temporary 5-HT1A receptor overexpression during embryonic and perinatal development causes long-term memory impairment. |
| Species: |
Mouse |
| Tissue: |
|
| Technique: |
Transgenesis. |
| References: |
11 |
|
|
| 5-HT1A receptor knockout mice show increases in typical anxiety and stress responses. |
| Species: |
Mouse |
| Tissue: |
|
| Technique: |
Gene targeting in embryonic stem cells. |
| References: |
12-14 |
|
|
| 5-HT1A receptor knockout mice exhibit down-regulation of the 5-HT transporter. |
| Species: |
Mouse |
| Tissue: |
|
| Technique: |
Gene targeting in embryonic stem cells. |
| References: |
15 |
|
|
| 5-HT1A receptor knockout mice exhibit a deficit in hippocampal-dependent learning and memory as well as higher limbic excitability. |
| Species: |
Mouse |
| Tissue: |
|
| Technique: |
Gene targeting in embryonic stem cells. |
| References: |
16 |
|
|
| 5-HT1A receptor knockout mice exhibit altered decision making abilities and response inhibition. |
| Species: |
Mouse |
| Tissue: |
|
| Technique: |
Gene targeting in embryonic stem cells. |
| References: |
17 |
|
|
Biologically Significant Variants
|
| Two polymorphisms, Gly22 -> Ser and Ile28 -> Val, have been found to alter the extracellular amino terminal region of the receptor. |
| Type: |
Single nucletide polymorphisms. |
| Species: |
Human |
| References: |
18 |
|
|
| The polymorphism Arg219 -> Leu has been associated with Tourette's syndrome. |
| Type: |
Single nucleotide polymorphism. |
| Species: |
Human |
| References: |
19 |
|
|
| The polymorphism Ala50 -> Val, occurring in transmembrane 1, results in a loss of response to 5-HT. |
| Type: |
Single nucleotide polymorphism. |
| Species: |
Human |
| References: |
20 |
|
|
To cite this receptor data page, please use the following:
Rodrigo Andrade, Nicholas M. Barnes, Gordon Baxter, Joel Bockaert, Theresa Branchek, Marlene L. Cohen, Aline Dumuis, Richard M. Eglen, Manfred Göthert, Mark Hamblin, Michel Hamon, Paul R. Hartig, René Hen, Katharine Herrick-Davis, Rebecca Hills, Daniel Hoyer, Patrick P. A. Humphrey, Klaus Peter Latté, Luc Maroteaux, Graeme R. Martin, Derek N. Middlemiss, Ewan Mylecharane, Stephen J. Peroutka, Pramod R. Saxena, Andrew Sleight, Carlos M. Villalon, Frank Yocca.
5-Hydroxytryptamine receptors: 5-HT1A. Last modified on 2010-08-03. Accessed on 2010-09-03. IUPHAR database (IUPHAR-DB), http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=1.
Contact us | Print | Back to top | Help